New GLP

Updated 2025 GLP-1 guidelines for type 2 diabetes , including clinical insights, prescribing tips, and what healthcare providers need to know.

The ADA Guidelines 2025 reaffirm metformin as the first-line therapy for Type 2 diabetes unless contraindicated. However, the guidelines give increasing prominence to GLP-1 receptor agonists and SGLT2 inhibitors for patients with cardiovascular or kidney disease, even at early stages of diabetes .
2025 ADA Guidelines

The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which - for the first time - includes recommendations for CGM use in type 2 diabetes , the use of GLP-1 drugs for kidney and heart health, and more.
The American Diabetes Association updated the pharmacological glycemic treatment of their "Standards of Care in Diabetes 2025 " to better reflect the use of glucagon-like peptide-1 ( GLP-1 ) medication and treatment of concurrent conditions, such as weight, cardiovascular, and kidney issues. 1

Summary of Revisions
The field of diabetes care is rapidly changing as new research, technology, and treatments that can improve the health and well-being of people with diabetes continue to emerge. With annual updates since 1989, the American Diabetes Association has long been a leader in producing guidelines that capture the most current state of the field.
The American Diabetes Association (ADA) recently released its 2025 Standards of Care. 1 The updated guidelines bring a fresh focus on diabetes monitoring and treatment, with a stronger call to action to address weight as a key risk factor for the condition. It's important to understand what these changes could mean for your plan members who have or are at risk for diabetes - and what these ...

Changes to the Standards of Care in Diabetes2025
The American Diabetes Association's (ADA) Standards of Care in Diabetes informs health care professionals about the latest evidence for diagnosing and managing diabetes . The 2025 Standards of Care includes updates to nearly all sections, including revised recommendations for diabetes medications type 1 diabetes testing evidence-based eating patterns The updated Standards of Care also ...
Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes.

Stay Current on Med Recommendations for Diabetes
You'll continue to see SGLT2 inhibitors and GLP-1 agonists gain traction as first-line agents for many adults with type 2 diabetes ... Learn more with Pharmacist's Letter.







The standards for diabetes management from the American Diabetes Association (ADA) have evolved significantly in recent years, and their 2025 standards recommend SGLT2 inhibitors and GLP1 RAs as first-line, glucose-lowering medications for all patients with diabetes . 2 Moreover, the recommendation highlights the use of GLP1 RAs for the primary ...